Cormedix Q2 EPS $(0.25) Misses $(0.24) Estimate
Portfolio Pulse from Benzinga Newsdesk
Cormedix reported Q2 losses of $(0.25) per share, missing the analyst consensus estimate of $(0.24) by 4.17 percent. This represents a 31.58 percent increase in losses compared to the same period last year.
August 08, 2023 | 11:42 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cormedix's Q2 earnings missed analyst estimates, with losses increasing by 31.58% compared to the same period last year.
Cormedix's Q2 earnings missed analyst estimates, which is typically a negative signal for the market. The increase in losses compared to the same period last year further exacerbates this negative impact. This could lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100